Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer

International Journal of Surgery

Volumn 7, Issue 3, 2009, Pages 272-275

  Hidar, Samir ^a   Bibi, Mohamed ^a   Gharbi, Olfa ^a   Tebra, Sameh ^a   Trabelsi, Amel ^a   Korbi, Sadok ^a   Bouaouina, Nouredine ^a   Ben Ahmed, Slim ^a   Khaïri, Hédi ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Inflammatory breast cancer; Modified radical mastectomy; Neoadjuvant chemotherapy; Sentinel lymph node biopsy

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATORY BREAST CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; INFLAMMATION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; SENTINEL LYMPH NODE BIOPSY;

EID: 67349128028     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2009.04.012     Document Type: Article

References (56)

1. Cariati M., Bennett-Britton T.M., Pinder S.E., and Purushotham A.D. "Inflammatory" breast cancer. Surg Oncol 14 (2005) 133-143
2. Hance K.W., Anderson W.F., Devesa S.S., Young H.A., and Levine P.H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
3. Miller A.R., Thomason V.E., Yeh I.T., Alrahwan A., Sharkey F.E., Stauffer J., et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 9 (2002) 243-247
4. Kang S.H., Kim S.K., Kwon Y., Kang H.S., Kang J.H., Ro J., et al. Decreased identification rate of sentinel lymph node after neoadjuvant chemotherapy. World J Surg 28 (2004) 1019-1024
5. Fernández A., Cortés M., Benito E., Azpeitia D., Prieto L., Moreno A., et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 22 (2001) 361-366
6. Boussen H., Bouzaiene H., Ben Hassouna J., Gamoudi A., Benna F., and Rahal K. Inflammatory breast cancer in Tunisia: reassessment of incidence and clinicopathological features. Semin Oncol 35 (2008) 17-24
7. Singletary. SE. Surgical management of inflammatory breast cancer. Semin Oncol 35 (2008) 72-77
8. Sapunar F., and Smith I.E. Neoadjuvant chemotherapy for breast cancer. Ann Med 32 (2000) 43-50
9. Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R.G., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
10. Kuerer H.M., Sahin A.A., Hunt K.K., Newman L.A., Breslin T.M., Ames F.C., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastasis before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 (1999) 72-78
11. Johnston S., Trudeau M., Kaufman B., Boussen H., Blackwell K., LoRusso P., et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 1 26 (2008) 1066-1072
12. Lyman G.H., Giuliano A.E., Somerfield M.R., Benson III A.B., Bodurka D.C., Burstein H.J., et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 23 (2005) 7703-7720
13. Stearns V., Ewing C.A., Slack R., Penannen M.F., Hayes D.F., and Tsangaris T.N. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9 (2002) 235-242
14. Chia S., Swain S.M., Byrd D.R., and Mankoff D.A. Locally advanced and inflammatory breast cancer. J Clin Oncol 26 (2008) 786-790
15. Singletary S.E., and Connolly J.L. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56 (2006) 37-47
16. Shen J., Gilcrease M.Z., Babiera G.V., Ross M.I., Meric-Bernstam F., Feig B.W., et al. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109 (2007) 1255-1263
17. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer 14 (2007) 10-15
18. Nason K.S., Anderson B.O., Byrd D.R., Dunnwald L.K., Eary J.F., Mankoff D.A., et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89 (2000) 2187-2194
19. Tafra L., Verbanac K.M., and Lannin D.R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 182 (2001) 312-315
20. Breslin T.M., Cohen L., Sahin A., Fleming J.B., Kuerer H.M., Newman L.A., et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18 (2000) 3480-3486
21. Julian T.B., Patel N., Dusi D., Olson P., Nathan G., Jasnosz K., et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 182 (2001) 407-410
22. Haid A., Tausch C., Lang A., Lutz J., Fritzsche H., Peschina W., et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer 92 (2001) 1080-1084
23. Brady E.W. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 8 (2002) 97-100
24. Balch G.C., Mithani S.K., Richards K.R., Beauchamp R.D., and Kelley M.C. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol 10 (2003) 616-621
25. Piato J.R., Barros A.C., Pincerato K.M., Sampaio A.P., and Pinotti J.A. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study. Eur J Surg Oncol 29 (2003) 118-120
26. Schwartz G.F., and Meltzer A.J. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 9 (2003) 374-379
27. Patel N.A., Piper G., Patel J.A., Malay M.B., and Julian T.B. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg 70 (2004) 696-699
28. Lang J.E., Esserman L.J., Ewing C.A., Rugo H.S., Lane K.T., Leong S.P., et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy. Effect of clinical node status at presentation. J Am Coll Surg 199 (2004) 856-862
29. Mamounas E.P., Brown A., Anderson S., Smith R., Julian T., Miller B., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 (2005) 2694-2702
30. Tausch C., Konstantiniuk P., Kugler F., Reitsamer R., Roka S., Pöstlberger S., et al. Austrian Sentinel Node Study Group. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol 15 (2008) 3378-3383
31. Lee S., Kim E.Y., Kang S.H., Kim S.W., Kim S.K., Kang K.W., et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat 102 (2007) 283-288
32. Newman E.A., Sabel M.S., Nees A.V., Schott A., Diehl K.M., Cimmino V.M., et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol 14 (2007) 2946-2952
33. Yamamoto M., Mehta R.S., Baick C.H., Su M.Y., Lane K.T., Butler J.A., et al. The predictive value of sentinel lymph node biopsy in locally advanced breast cancer patients who have undergone neoadjuvant chemotherapy. Am Surg 73 (2007) 977-980
34. Hino M., Sano M., Sato N., and Homma K. Sentinel lymph node biopsy after neoadjuvant chemotherapy in a patient with operable breast cancer. Surg Today 38 (2008) 585-591
35. Xing Y., Foy M., Cox D.D., Kuerer H.M., Hunt K.K., and Cormier J.N. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93 (2006) 539-546
36. Shimazu K., Tamaki Y., Taguchi T., Akazawa K., Inoue T., and Noguchi S. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer 100 (2004) 2555-2561
37. Ben Hamida A., Labidi I.S., Mrad K., Charafe-Jauffret E., Ben Arab S., Esterni B., et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 8 (2008) 28
38. Kleer C.G., van Golen K.L., and Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Research 2 (2000) 423-429
39. Anderson W.F., Chu K.C., and Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities?. J Clin Oncol 15 21 (2003) 2254-2259
40. Yang R, Cheung MC, Hurley J, Huang Y, Zimmers TA. A comprehensive evaluation of outcomes for inflammatory breast cancer. Breast Cancer Res Treat, in press.
41. Charafe-Jauffret E., Mrad K., Intidhar Labidi S., Ben Hamida A., Ben Romdhane K., Ben Abdallah M., et al. Inflammatory breast cancers in Tunisia and France show similar immunophenotypes. Breast 16 (2007) 352-358
42. Lê M.G., Arriagada R., Bahi J., Pfeiffer F., Cammoun M., Tabbane F., et al. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with noninflammatory breast cancer?. Breast 15 (2006) 355-362
43. Papa M.Z., Zippel D., Kaufman B., Shimon-Paluch S., Yosepovich A., Oberman B., et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol 98 (2008) 403-406
44. Bedrosian I., Reynolds C., Mick R., Callans L.S., Grant C.S., Donohue J.H., et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors, sentinel lymph node biopsy in patients with large primary breast tumors. Cancer 88 (2000) 2540-2545
45. Kuerer H.M., Newman L.A., Buzdar A.U., Hunt K.K., Dhingra K., Buchholz T.A., et al. Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. Am J Surg 176 (1998) 502-509
46. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 (2003) 4165-4174
47. Rouzier R., Extra J.M., Klijanienko J., Falcou M.C., Asselain B., Vincent-Salomon A., et al. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 1304-1310
48. Jones J.L., Zabicki K., Christian R.L., Gadd M.A., Hughes K.S., Lesnikoski B.A., et al. A comparaison of sentinel lymph node biopsy before and after neoadjuvant chemotherapy; timing is important. Am J Surg 190 (2005) 517-520
49. Jeruss J.S., Newman L.A., Ayers G.D., Cristofanilli M., Broglio K.R., Meric-Bernstam F., et al. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Cancer 112 (2008) 2646-2654
50. Kinoshita T., Tagasugi M., Iwamoto E., Akashi-Tanaka S., Fukutomi T., and Terui S. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg 191 (2006) 225-229
51. Zavagno G., Rubello D., Franchini Z., Meggiolaro F., Ballarin A., Casara D., et al. Axillary sentinel lymph nodes in breast cancer: a single lymphatic pathway drains the entire mammary gland. Eur J Surg Oncol 31 (2005) 479-484
52. Nastro P., Sodo M., Dodaro C.A., Gargiulo S., Acampa W., Bracale U., et al. Intraoperative radiochromoguided mapping of sentinel lymph node in colon cancer. Tumori 88 (2002) 352-353
53. Zavagno G., Meggiolaro F., Rossi C.R., Casara D., Pescarini L., Marchet A., et al. Eur J Surg Oncol 28 (2002) 701-704
54. Rovera F., Frattini F., Marelli M., Corben A.D., Dionigi G., Boni L., et al. Axillary sentinel lymph node biopsy: an overview. Int J Surg 6 (2008) S109-S112
55. Yi M., Meric-Bernstam F., Ross M.I., Akins J.S., Hwang R.F., Lucci A., et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer 113 (2008) 30-37
56. Herrada J., Iyer R.B., Atkinson E.N., Sneige N., Buzdar A.U., Hortobagyi G.N., et al. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin Cancer Res 3 (1997) 1565-1569